Boehringer Ingelheim invests in Amal Therapeutics

Boehringer Ingelheim has provided a new investment in Amal Therapeutics, which is working to develop innovative cancer vaccines.

Amal has completed a three million Swiss franc (2.16 million pound) Series A financing round with the Boehringer Ingelheim Venture Fund as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round.

The funds will be used to progress the preclinical development of its lead vaccine ATP124, which is being assessed as a means of protecting against colorectal cancer. This will also help the firm to further develop its KISIMA technology platform for therapeutic tumour vaccination.

Amal's novel technology works by generating potent long lasting antitumour immunity and avoid tumour immune escape.

Dr Knut Elbers, the Boehringer Ingelheim Venture Fund representative on Amal's board, said: "We are confident that Amal's Kisima technology could revolutionise the peptide-based cancer vaccine field – bringing an exciting new technology to the patient."

This comes after the firm announced a new immunology-focused collaboration with AbbVie earlier this month.